DBM
MCID: LKM056
MIFTS: 48

Leukemia, Chronic Lymphocytic 2 (DBM)

Categories: Blood diseases, Bone diseases, Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for Leukemia, Chronic Lymphocytic 2

MalaCards integrated aliases for Leukemia, Chronic Lymphocytic 2:

Name: Leukemia, Chronic Lymphocytic 2 56 29
Leukemia, Chronic Lymphocytic, Susceptibility to, 2 56 13
B-Cell Malignancy, Low-Grade 56 71
Leukemia, Chronic Lymphocytic, B-Cell; Bcll 56
Leukemia, Chronic Lymphocytic, B-Cell 56
Disrupted in B-Cell Malignancy; Dbm 56
Lymphocytic Leukemia Chronic B-Cell 54
Disrupted in B-Cell Malignancy 56
Chronic Lymphocytic Leukemia 71
Clls2 56
Bcll 56
Dbm 56

Characteristics:

OMIM:

56
Inheritance:
autosomal dominant (13q14)


HPO:

31
leukemia, chronic lymphocytic 2:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

OMIM 56 109543
ICD10 32 C91.1
MedGen 41 C1868683
UMLS 71 C0023434 C1868683

Summaries for Leukemia, Chronic Lymphocytic 2

MalaCards based summary : Leukemia, Chronic Lymphocytic 2, also known as leukemia, chronic lymphocytic, susceptibility to, 2, is related to cll/sll and leukemia, chronic lymphocytic, and has symptoms including fatigue, edema and chest pain. An important gene associated with Leukemia, Chronic Lymphocytic 2 is CLLS2 (Disrupted In B-Cell Neoplasia), and among its related pathways/superpathways are Hematopoietic Stem Cells and Lineage-specific Markers and Interleukin-4 and 13 signaling. The drugs alemtuzumab and Valganciclovir have been mentioned in the context of this disorder. Affiliated tissues include b cells, t cells and bone, and related phenotypes are chronic lymphatic leukemia and hematopoietic system

More information from OMIM: 109543

Related Diseases for Leukemia, Chronic Lymphocytic 2

Diseases in the Leukemia, Chronic Lymphocytic family:

Leukemia, Chronic Lymphocytic 2 Leukemia, Chronic Lymphocytic 1
Leukemia, Chronic Lymphocytic 3 Leukemia, Chronic Lymphocytic 4
Leukemia, Chronic Lymphocytic 5 Adult Acute Lymphocytic Leukemia

Diseases related to Leukemia, Chronic Lymphocytic 2 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 66)
# Related Disease Score Top Affiliating Genes
1 cll/sll 29.5 ZAP70 CD5 CD38 ATM
2 leukemia, chronic lymphocytic 27.5 ZAP70 MS4A1 MCL1 IGHM FCER2 CLLS2
3 lymphoma 27.2 MS4A1 MCL1 CD5 CD38 BCL3 BCL2
4 periodontitis, chronic 10.3
5 periodontitis 10.3
6 osteonecrosis 10.3
7 gingival recession 10.3
8 rhabdomyosarcoma 10.2
9 bone resorption disease 10.2
10 spinal stenosis 10.2
11 waldenstroem's macroglobulinemia 10.1 CD5 CD38
12 cryoglobulinemia, familial mixed 10.1 IGHM CD5
13 chromosomal triplication 10.1 ZAP70 BCL3
14 anemia, autoimmune hemolytic 10.1 ZAP70 CD5
15 endocrine exophthalmos 10.1 CD5 ATM
16 spherocytosis, type 5 10.1 MCL1 CD38
17 plasma protein metabolism disease 10.1 CD5 CD38
18 colorectal cancer 10.0
19 hepatocellular carcinoma 10.0
20 papillomatosis, confluent and reticulated 10.0
21 retinoblastoma 10.0
22 suppression of tumorigenicity 12 10.0
23 leukemia, chronic myeloid 10.0
24 scoliosis 10.0
25 sarcoma 10.0
26 gestational diabetes 10.0
27 hyperinsulinism 10.0
28 skin carcinoma 10.0
29 hyperglycemia 10.0
30 spindle cell sarcoma 10.0
31 familial retinoblastoma 10.0
32 myeloid leukemia 10.0
33 hypoglycemia 10.0
34 47,xyy 10.0
35 dentinogenesis imperfecta type 2 10.0
36 plasmablastic lymphoma 10.0 MS4A1 CD38
37 cold agglutinin disease 9.9 MS4A1 IGHM
38 leukocyte disease 9.9 MCL1 CD5 CD38
39 intravascular large b-cell lymphoma 9.9 CD5 BCL2
40 b-cell non-hodgkin lymphoma 9.8 MS4A1 ATM
41 extramedullary plasmacytoma 9.8 CD38 BCL2
42 lymphoplasmacytic lymphoma 9.8 ZAP70 MS4A1 CD5
43 combined t cell and b cell immunodeficiency 9.8 ZAP70 CD38 ATM
44 t-cell prolymphocytic leukemia 9.8 MS4A1 ATM
45 plasma cell neoplasm 9.7 CD5 CD38
46 primary central nervous system lymphoma 9.7 IGHM BCL2
47 diffuse large b-cell lymphoma 9.7 MCL1 CD5 CD38
48 chromosome 13q14 deletion syndrome 9.7 ZAP70 CD5 CD38 ATM
49 richter's syndrome 9.7 ZAP70 CD5 CD38 ATM
50 lymphoma, mucosa-associated lymphoid type 9.6 ZAP70 CD5 BCL2

Graphical network of the top 20 diseases related to Leukemia, Chronic Lymphocytic 2:



Diseases related to Leukemia, Chronic Lymphocytic 2

Symptoms & Phenotypes for Leukemia, Chronic Lymphocytic 2

Human phenotypes related to Leukemia, Chronic Lymphocytic 2:

31
# Description HPO Frequency HPO Source Accession
1 chronic lymphatic leukemia 31 HP:0005550

Symptoms via clinical synopsis from OMIM:

56
Oncology:
b-cell chronic lymphocytic leukemia (cll)

Clinical features from OMIM:

109543

UMLS symptoms related to Leukemia, Chronic Lymphocytic 2:


fatigue, edema, chest pain, angina pectoris

MGI Mouse Phenotypes related to Leukemia, Chronic Lymphocytic 2:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.61 ATM BCL2 BCL3 CD38 CD5 FCER2
2 immune system MP:0005387 9.28 ATM BCL2 BCL3 CD38 CD5 FCER2

Drugs & Therapeutics for Leukemia, Chronic Lymphocytic 2

Drugs for Leukemia, Chronic Lymphocytic 2 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 421)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
alemtuzumab Approved, Investigational Phase 4 216503-57-0
2
Valganciclovir Approved, Investigational Phase 4 175865-60-8 64147
3
Promethazine Approved, Investigational Phase 4 60-87-7 4927
4
Acetaminophen Approved Phase 4 103-90-2 1983
5
Diphenhydramine Approved, Investigational Phase 4 58-73-1, 147-24-0 3100
6
Thiotepa Approved, Investigational Phase 4 52-24-4 5453
7
Heparin Approved, Investigational Phase 4 9005-49-6 46507594 772
8
Pancrelipase Approved, Investigational Phase 4 53608-75-6
9
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
10
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
11
Chlorambucil Approved Phase 4 305-03-3 2708
12 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
13 Vaccines Phase 4
14 Thymoglobulin Phase 4
15 calcium heparin Phase 4
16 pancreatin Phase 4
17 Hydrocortisone 17-butyrate 21-propionate Phase 4
18 Hydrocortisone hemisuccinate Phase 4
19 Hematinics Phase 4
20 Epoetin alfa Phase 4 113427-24-0
21
Pixantrone Approved, Investigational Phase 3 144510-96-3
22
Cefepime Approved, Investigational Phase 3 88040-23-7 5479537
23
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
24
Ofloxacin Approved Phase 3 82419-36-1 4583
25
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
26
Cladribine Approved, Investigational Phase 3 4291-63-8 20279
27
Darbepoetin alfa Approved, Investigational Phase 3 11096-26-7, 209810-58-2
28
Cisplatin Approved Phase 3 15663-27-1 2767 441203 84093
29
Iron Approved, Experimental Phase 3 15438-31-0, 7439-89-6 27284 23925
30
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
31
Dalteparin Approved Phase 3 9005-49-6
32
Tinzaparin Approved Phase 3 9041-08-1, 9005-49-6 25244225
33
Caspofungin Approved Phase 3 162808-62-0, 179463-17-3 2826718 468682
34
Tazobactam Approved Phase 3 89786-04-9 123630
35
Vancomycin Approved Phase 3 1404-90-6 14969 441141
36
Piperacillin Approved Phase 3 66258-76-2 43672
37
Amphotericin B Approved, Investigational Phase 3 1397-89-3 5280965 14956
38
Itraconazole Approved, Investigational Phase 3 84625-61-6 55283
39
Captopril Approved Phase 3 62571-86-2 44093
40
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
41
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
42
Ribavirin Approved Phase 3 36791-04-5 37542
43
Palivizumab Approved, Investigational Phase 3 188039-54-5
44
Acyclovir Approved Phase 3 59277-89-3 2022
45
Zanubrutinib Approved, Investigational Phase 3 1691249-45-2
46
Obinutuzumab Approved, Investigational Phase 3 949142-50-1
47
ofatumumab Approved Phase 3 679818-59-8 6918251
48
Idelalisib Approved Phase 3 870281-82-6
49
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
50
Mycophenolic acid Approved Phase 3 24280-93-1 446541

Interventional clinical trials:

(show top 50) (show all 1337)
# Name Status NCT ID Phase Drugs
1 A Multicenter, Open-Label Study of Nipent, Cytoxan and Rituxan in Patients With Previously Untreated or Treated Chronic Lymphocytic Leukemia. Unknown status NCT00131313 Phase 4 Nipent, Cytoxan, Rituxan
2 Evaluation of the Immune Response After Vaccination Against Hepatitis B in Patients With Indolent Lymphoproliferative Disorders With no Treatment. Unknown status NCT01698866 Phase 4
3 1-Year Longitudinal Follow-up Study of Serologic Responses to 7-valent Pneumococcal Conjugated Vaccination and Opsonophagocytic Activities for Streptococcus Pneumoniae Among Patients With Human Immunodeficiency Virus Infection Unknown status NCT00885625 Phase 4
4 A Single-arm, International, Multi-center Trial Investigating the Efficacy and Safety of Ofatumumab Retreatment and Maintenance in CLL Patients Who Progressed Following Response or Stable Disease After Ofatumumab Treatment in Hx-CD20-406 Completed NCT00802737 Phase 4 Ofatumumab
5 The Duration of Humoral Immunity and the Memory Cell Function After Vaccination With 7-valent Pneumococcal Conjugate Vaccine in CLL Completed NCT00919321 Phase 4
6 A Multicenter Study to Confirm the Efficacy and Safety of Fludara i.v. (Fludarabine Phosphate, SH L 573), Administered in 6 Treatment Cycles (1 Treatment Cycle: 5-consecutive Day Dosing, Followed by an Observation Period of 23 Days) in Untreated Chronic Lymphocytic Leukemia Patients With Anemia and/or Thrombocytopenia Completed NCT00220311 Phase 4 Fludarabine Phosphate (Fludara)
7 Treatment of Chronic Lymphocytic Leukemia With the Use of an Antiviral Compound - a Proof of Principle Study Completed NCT01255644 Phase 4 Valganciclovir
8 A Randomized Study to Assess the Effect on Response Rate of MabThera (Rituximab) Added to a Standard Chemotherapy, Bendamustine or Chlorambucil, in Patients With Chronic Lymphocytic Leukemia Completed NCT01056510 Phase 4 bendamustine;chlorambucil;rituximab [MabThera/Rituxan]
9 The Effects of PROCRIT (Epoetin Alfa) on Hemoglobin, Symptom Distress, and Quality of Life During Chemotherapy in Lymphoma, Chronic Lymphocytic Leukemia or Multiple Myeloma Patients With Mild to Moderate Anemia Completed NCT00524407 Phase 4 Epoetin alfa
10 Evaluation of Allogeneic Marrow Transplants Depleted of T-Cells by CD34+ Selection in Patients Undergoing Transplantation With an Unrelated Matched or 1 Antigen Mismatched Donor or a 1 Antigen Mismatched Related Donor Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
11 Study Evaluating Rapid Infusion Rituximab in Patients With Autoimmune Diseases Completed NCT02040116 Phase 4 Rituximab Infusion
12 Alemtuzumab Versus Thymoglobulin Induction Therapy in Kidney and Pancreas Transplantation Completed NCT00331162 Phase 4 Alemtuzumab;Anti-Thymocyte Globulin
13 A Prospective, Multicenter, Open Label Single Arm Phase IV Clinical Trial to Assess Safety of ImbruvicaTM (Ibrutinib Capsules 140 mg) in Indian Patients With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion Recruiting NCT03190330 Phase 4 Ibrutinib 420 mg;Ibrutinib 560 mg
14 Prospective Study of Efficacy and Safety of RFC (Rituximab, Fludarabine, Cyclophosphamide) Regimen as a First-Line Therapy in Patients With B-Cell Chronic Lymphocytic Leukemia and Favorable Somatic Status Terminated NCT01271010 Phase 4 Cyclophosphamide;Fludarabine;Rituximab
15 Open Multicentric Study to Assess the Hematopoyetic Response in Terms of Increase of Hemoglobin Levels of Patients With Anemia Related to Non- Hodgkin Lymphoma, Chronic Lymphocytic Leukemia or Multiple Myeloma, Treated With Erythropoietin B (Recormon) Using Pre-filled Syringe With 30000 IU, as Well as to Quantify the Risk Factors of Anemia and Its Impact on Quality of Life Related to Treatment Terminated NCT02608060 Phase 4 Epoetin Beta
16 Prospective Randomized Study to Compare Efficacy and Safety of RFC-Lite (Rituximab, Fludarabine, Cyclophosphamide) Regimen With LR (Rituximab, Chlorambucil) as a First-Line Therapy in Patients With B-Cell Chronic Lymphocytic Leukemia and Unfavorable Somatic Status Terminated NCT01283386 Phase 4 Chlorambucil;Cyclophosphamide;Fludarabine;Rituximab
17 Study of Bendamustine Hydrochloride Injection in Previously Untreated Chronic Lymphocytic Leukemia Patients Unknown status NCT01657955 Phase 3 Bendamustine Hydrochloride Injection;Chlorambucil
18 Clinical Study of Chemoimmunotherapy With Fresh Frozen Plasma, High Dose Methylprednisolone and Rituximab for Ultra-high Risk Chronic Lymphocytic Leukemia Unknown status NCT01670812 Phase 3 FFP+HDMP+Rituximab
19 Low Dose Chlorambucil Maintenance Vs. No Treatment Following High-Dose Chlorambucil Induction In Patients With Advanced B-Chronic Lymphocytic Leukemia. A Randomized Phase III Study Of The EORTC LG (CLL-3) Unknown status NCT00017108 Phase 3 chlorambucil;cyclophosphamide;fludarabine phosphate
20 A Randomized Phase III Trial Comparing the Combination of Fludarabine, BBR 2778 (Pixantrone) and Rituximab (FP-R) With the Combination of Fludarabine and Rituximab (F-R) in the Treatment of Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Unknown status NCT00551239 Phase 3 fludarabine phosphate;pixantrone dimaleate
21 Randomized Controlled Study of Iron Supplementation to Support the Response to Recombinant Human Erythropoietin for the Treatment of Chemotherapy-Induced Anaemia Unknown status NCT00482716 Phase 3
22 Combination of Ibrutinib and As2O3 in the Treatment of CLL Unknown status NCT02757040 Phase 3 Ibrutinib combined with As2O3;ibrutinib
23 Multicenter, Double-Blind, Randomized Study to Compare the Safety and Efficacy of Levofloxacin With That of Cefepime in the Treatment of Fever and Neutropenia - Phase IIIB Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
24 A Randomized Double-Blind Controlled Trial of Ketamine Versus Placebo in Conjunction With Best Pain Management in Neuropathic Pain in Cancer Patients Unknown status NCT01316744 Phase 3 ketamine hydrochloride
25 Effect of Rituximab in Treatment of Primary Membranoproliferative Glomerulonephritis Unknown status NCT03180723 Phase 3 Rituximab;Cyclosporin
26 A Randomized Trial of Thymoglobulin to Prevent Chronic Graft Versus Host Disease in Patients Undergoing Hematopoietic Progenitor Cell Transplantation (HPCT) From Unrelated Donors Unknown status NCT01217723 Phase 3
27 A Randomized Phase III Study to Assess Intensification of the Conditioning Regimen for Allogenic Stem Cell Transplantation (ALLO-SCT) for Leukemia or Myelodysplastic Syndrome With a High Risk of Relapse Unknown status NCT00002989 Phase 3 busulfan;cyclophosphamide;idarubicin;melphalan
28 Phase III Trial of Combined Immunochemotherapy With Fludarabine, Cyclophosphamide and Rituximab (FCR) Versus Chemotherapy With Fludarabine and Cyclophosphamide (FC) Alone in Patients With Previously Untreated Chronic Lymphocytic Leukaemia Completed NCT00281918 Phase 3 Rituximab;Cyclophosphamide;Fludarabine Phosphate
29 Prognostic Factors and Risk-Adapted Therapy in Patients With Early Stage Chronic Lymphocytic Leukemia Completed NCT00262782 Phase 3 Fludarabine
30 Fludarabine Versus Chlorambucil in First Line Therapy of Elderly Patients (More Than 65 Years) With Advanced Chronic Lymphocytic Leukemia Completed NCT00262795 Phase 3 Fludarabine;Chlorambucil
31 International, Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation Alone in Patients With Chronic Lymphocytic Leukemia Completed NCT01118234 Phase 3 Rituximab
32 Bendamustine Versus Fludarabine as 2nd-line Treatment in Chronic Lymphocytic Leukemia, Stage BINET B+C / RAI II-IV Completed NCT01423032 Phase 2, Phase 3 bendamustine;Fludarabine
33 Phase III Randomized Trial of Fludarabine and Cyclophosphamide Versus Fludarabine for Previously Untreated Chronic Lymphocytic Leukemia Completed NCT00003764 Phase 3 cyclophosphamide;fludarabine phosphate
34 A Phase III, Open Label, Randomized Trial of Ofatumumab Added to Fludarabine-Cyclophosphamide vs. Fludarabine-Cyclophosphamide Combination in Subjects With Relapsed Chronic Lymphocytic Leukemia Completed NCT00824265 Phase 3 OFC Infusion;FC infusion
35 A Randomized Phase III Trial to Determine Whether Conjugated Pneumococcal Vaccine Can Improve the Immune Responsiveness Compared to Polyclonal Pneumococcal Vaccine in Patients With Untreated Chronic Lymphocytic Leukemia Completed NCT01892618 Phase 3 Prevenar 13;Pneumovax
36 Open-label, Multicenter, Randomized, Comparative, Phase III Study to Evaluate the Efficacy and Safety of FCR vs. FC Alone in Previously Treated Patients With CD20 Positive B-cell CLL Completed NCT00090051 Phase 3 Rituximab;Fludarabine Phosphate;Cyclophosphamide
37 A Prospective, Randomized, Open Label, Phase III Trial of Fludarabine, Cyclophosphamide, and Rituximab vs. Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-cell Chronic Lymphocytic Leukemia Completed NCT00254163 Phase 3 Fludarabine;Cyclophosphamide;Rituximab;Pentostatin
38 Darbepoetin Alfa in Patients With Chronic Lymphocytic Leukemia and Comorbidity Completed NCT00281892 Phase 3 Fludarabine mono
39 A Randomized, Multi-center, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Subjects With Treatment-naïve Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Completed NCT02264574 Phase 3 Ibrutinib;Obinutuzumab;Chlorambucil
40 A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Completed NCT01578707 Phase 3 ofatumumab;ibrutinib
41 Fludarabine Versus Fludarabine Plus Cyclophosphamide in First Line Therapy of Younger Patients (Up to 65 Years) With Advanced Chronic Lymphocytic Leukemia (CLL) Completed NCT00276848 Phase 3 Fludarabine plus Cyclophosphamide;Fludarabine
42 Phase III Trial of Combined Immunochemotherapy With Fludarabine, Cyclophosphamide and Rituximab (FCR) Versus Bendamustine and Rituximab (BR) in Patients With Previously Untreated Chronic Lymphocytic Leukaemia Completed NCT00769522 Phase 3 Bendamustine;Cyclophosphamide;Fludarabine
43 Randomized Phase-III Trial Comparing Fludarabine and Cyclophosphamide Plus Rituximab (FCR) to FC and MabCampath (FCCam) for Previously Untreated Fit Patients With Chronic Lymphocytic Leukemia (CLL) Completed NCT00564512 Phase 3 cyclophosphamide;fludarabine
44 Chronic Lymphocytic Leukemia Trial 4: A Randomized Comparison of Chlorambucil, Fludarabine and Fludarabine Plus Cyclophosphamide Completed NCT00004218 Phase 3 chlorambucil;cyclophosphamide;doxorubicin hydrochloride;fludarabine phosphate;prednisolone;vincristine sulfate
45 Randomized Phase III Trial Comparing Early Treatment With Fludarabine/Cyclophosphamide + Rituximab Versus Deferred Treatment in Untreated Binet Stage A Patients With CLL and High Risk of Progression Completed NCT00275054 Phase 3 Fludarabine;Cyclophosphamide
46 Randomized Phase III Trial Evaluating the Role of Autologous Stem Cell Transplantation in Previously Untreated Patients With Stage B and C Chronic Lymphocytic Leukemia Completed NCT00931645 Phase 3
47 A Phase III Study to Evaluate the Efficacy and Safety of Front-Line Therapy With Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Chronic Lymphocytic Leukemia Completed NCT00046683 Phase 3 alemtuzumab
48 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia Completed NCT01569295 Phase 3 Idelalisib;Rituximab;Bendamustine;Placebo to match idelalisib
49 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia Completed NCT01539512 Phase 3 Idelalisib;Rituximab;Placebo to match idelalisib
50 A Phase 3 Study to Evaluate the Efficacy and Safety of Dinaciclib or Ofatumumab in Subjects With Refractory Chronic Lymphocytic Leukemia Completed NCT01580228 Phase 3 Dinaciclib;Ofatumumab

Search NIH Clinical Center for Leukemia, Chronic Lymphocytic 2

Inferred drug relations via UMLS 71 / NDF-RT 50 :


alemtuzumab
Chlorambucil
Cladribine
Cyclophosphamide
etoposide phosphate
fludarabine
Fludarabine phosphate
Ibrutinib
Ifosfamide
Immunoglobulins, Intravenous
mercaptopurine
pegaspargase
Uracil Mustard

Genetic Tests for Leukemia, Chronic Lymphocytic 2

Genetic tests related to Leukemia, Chronic Lymphocytic 2:

# Genetic test Affiliating Genes
1 Leukemia, Chronic Lymphocytic 2 29

Anatomical Context for Leukemia, Chronic Lymphocytic 2

MalaCards organs/tissues related to Leukemia, Chronic Lymphocytic 2:

40
B Cells, T Cells, Bone, Bone Marrow, Myeloid, Breast, Nk Cells

Publications for Leukemia, Chronic Lymphocytic 2

Articles related to Leukemia, Chronic Lymphocytic 2:

(show top 50) (show all 321)
# Title Authors PMID Year
1
Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. 56
21205967 2011
2
Cloning and gene mapping of the chromosome 13q14 region deleted in chronic lymphocytic leukemia. 56
9205107 1997
3
Evidence for a new tumour suppressor locus (DBM) in human B-cell neoplasia telomeric to the retinoblastoma gene. 56
8490658 1993
4
Alterations of multiple tumor suppressor genes (p53 (17p13), p16INK4 (9p21), and DBM (13q14)) in B-cell chronic lymphocytic leukemia. 61 54
7576105 1995
5
ZAP70: a master regulator of adaptive immunity. 54
20135127 2010
6
IL-7 receptor is expressed on adult pre-B-cell acute lymphoblastic leukemia and other B-cell derived neoplasms and correlates with expression of proliferation and survival markers. 54
20060740 2010
7
Adipose tissue depots of Holstein cows are immune responsive: inflammatory gene expression in vitro. 54
19914024 2010
8
The Bcl-2 family as a rational target for the treatment of B-cell chronic lymphocytic leukaemia. 54
20156175 2010
9
Molecular profiling using tissue microarrays as a tool to identify predictive biomarkers in laryngeal cancer treated with radiotherapy. 54
20181625 2010
10
IL-21 and T follicular helper cells. 54
19933709 2010
11
Involvement of RhoH GTPase in the development of B-cell chronic lymphocytic leukemia. 54
19847197 2010
12
VEGF/VEGFR2 interaction down-regulates matrix metalloproteinase-9 via STAT1 activation and inhibits B chronic lymphocytic leukemia cell migration. 54
19965686 2010
13
Genetic and immunophenotypic profile of IGH@ rearrangement detected by fluorescence in situ hybridization in 149 cases of B-cell chronic lymphocytic leukemia. 54
19963136 2010
14
Strong correlation between VEGF and MCL-1 mRNA expression levels in B-cell chronic lymphocytic leukemia. 54
19487028 2009
15
Bi-directional activation between mesenchymal stem cells and CLL B-cells: implication for CLL disease progression. 54
19751240 2009
16
Protective effect of histamine H2 receptor antagonist ranitidine against rotenone-induced apoptosis. 54
19723537 2009
17
BAFF and APRIL expression in B-cell chronic lymphocytic leukemia: correlation with biological and clinical features. 54
19395025 2009
18
Cellular mechanisms underlying affective resiliency: the role of glucocorticoid receptor- and mitochondrially-mediated plasticity. 54
19595676 2009
19
Anticancer mechanisms of doxorubicin and zoledronic acid in breast cancer tumor growth in bone. 54
19789217 2009
20
The tyrosine kinase Syk regulates the survival of chronic lymphocytic leukemia B cells through PKCdelta and proteasome-dependent regulation of Mcl-1 expression. 54
19581935 2009
21
Serum level of CD26 predicts time to first treatment in early B-chronic lymphocytic leukemia. 54
19459926 2009
22
Naringin Protects against Rotenone-induced Apoptosis in Human Neuroblastoma SH-SY5Y Cells. 54
19885011 2009
23
Phosphorylation of the activation loop tyrosines is required for sustained Syk signaling and growth factor-independent B-cell proliferation. 54
19296913 2009
24
Prognostic irrelevance of HLA-G in B-cell chronic lymphocytic leukemia. 54
18241213 2009
25
HLA-G expression in B chronic lymphocytic leukemia: a new prognostic marker? 54
19298722 2009
26
Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells. 54
19092849 2009
27
ZAP-70 and Syk expression in canine lymphoid cells and preliminary results on leukaemia cases. 54
19144411 2009
28
[Immunohistochemical detection of ZAP-70 protein and its importance in the diagnostics of B-CLL]. 54
19534392 2009
29
Major vault protein may affect nonhomologous end-joining repair and apoptosis through Ku70/80 and bax downregulation in cervical carcinoma tumors. 54
19251084 2009
30
CD38 gene polymorphisms contribute to genetic susceptibility to B-cell chronic lymphocytic leukemia: evidence from two case-control studies in Polish Caucasians. 54
19240243 2009
31
High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation. 54
19074730 2009
32
TLR9-activating DNA up-regulates ZAP70 via sustained PKB induction in IgM+ B cells. 54
19050243 2008
33
Geldanamycin-induced Lyn dissociation from aberrant Hsp90-stabilized cytosolic complex is an early event in apoptotic mechanisms in B-chronic lymphocytic leukemia. 54
18768392 2008
34
The significance of soluble HLA-G plasma levels as well as messenger HLA-G for B-cell chronic lymphocytic leukemia (B-CLL). 54
18499249 2008
35
P2X7 gene polymorphisms do not appear to be a susceptibility gene locus in sporadic cases of systemic lupus erythematosus. 54
18937793 2008
36
IL-24 induces apoptosis of chronic lymphocytic leukemia B cells engaged into the cell cycle through dephosphorylation of STAT3 and stabilization of p53 expression. 54
18941194 2008
37
Detection of ZAP-70 in patients with chronic lymphocytic leukemia. 54
19145677 2008
38
Lipopolysaccharide activates NF-kappaB by TLR4-Bcl10-dependent and independent pathways in colonic epithelial cells. 54
18718996 2008
39
Molecular and transcriptional characterization of 17p loss in B-cell chronic lymphocytic leukemia. 54
18521849 2008
40
Purine-rich box-1-mediated reduced expression of CD20 alters rituximab-induced lysis of chronic lymphocytic leukemia B cells. 54
18794139 2008
41
Stimulation of iNOS expression and apoptosis resistance in B-cell chronic lymphocytic leukemia (B-CLL) cells through engagement of Toll-like receptor 7 (TLR-7) and NF-kappaB activation. 54
18474259 2008
42
The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells. 54
18497318 2008
43
FCRL2 expression predicts IGHV mutation status and clinical progression in chronic lymphocytic leukemia. 54
18314442 2008
44
DNA-dependent protein kinase is a therapeutic target and an indicator of poor prognosis in B-cell chronic lymphocytic leukemia. 54
18559621 2008
45
The impact of trisomy 12, retinoblastoma gene and P53 in prognosis of B-cell chronic lymphocytic leukemia. 54
18702872 2008
46
[In silico identification, molecular cloning and verification of a novel pig gene homologous to human BCL10 of innate immunity and its preliminary expression profiles in pigs]. 54
18550498 2008
47
MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia. 54
18467716 2008
48
Protein expression profiling of cytokines and cytokine receptors on purified chronic lymphocytic leukemia cells from patients with favourable prognostic indicators. 54
18398743 2008
49
Toll-like receptor 4 mediates induction of the Bcl10-NFkappaB-interleukin-8 inflammatory pathway by carrageenan in human intestinal epithelial cells. 54
18252714 2008
50
Targeting lipid metabolism by the lipoprotein lipase inhibitor orlistat results in apoptosis of B-cell chronic lymphocytic leukemia cells. 54
18079738 2008

Variations for Leukemia, Chronic Lymphocytic 2

Expression for Leukemia, Chronic Lymphocytic 2

Search GEO for disease gene expression data for Leukemia, Chronic Lymphocytic 2.

Pathways for Leukemia, Chronic Lymphocytic 2

GO Terms for Leukemia, Chronic Lymphocytic 2

Cellular components related to Leukemia, Chronic Lymphocytic 2 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell GO:0005623 9.35 MS4A1 MCL1 CD38 BCL2 ATM
2 external side of plasma membrane GO:0009897 8.92 MS4A1 IGHM FCER2 CD5

Biological processes related to Leukemia, Chronic Lymphocytic 2 according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.71 MCL1 CD38 BCL3 BCL2
2 thymus development GO:0048538 9.58 BCL2 ATM
3 ovarian follicle development GO:0001541 9.57 BCL2 ATM
4 neuron apoptotic process GO:0051402 9.56 BCL2 ATM
5 regulation of apoptotic process GO:0042981 9.56 MCL1 BCL3 BCL2 ATM
6 positive regulation of B cell proliferation GO:0030890 9.55 CD38 BCL2
7 T cell differentiation GO:0030217 9.54 ZAP70 BCL2
8 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 9.52 MCL1 BCL2
9 extrinsic apoptotic signaling pathway in absence of ligand GO:0097192 9.51 MCL1 BCL2
10 B cell proliferation GO:0042100 9.49 MS4A1 BCL2
11 spleen development GO:0048536 9.48 BCL3 BCL2
12 B cell activation GO:0042113 9.46 ZAP70 MS4A1
13 negative regulation of intrinsic apoptotic signaling pathway GO:2001243 9.43 MCL1 BCL2
14 negative regulation of anoikis GO:2000811 9.37 MCL1 BCL2
15 response to cytokine GO:0034097 9.33 MCL1 CD38 BCL2
16 oocyte development GO:0048599 9.32 BCL2 ATM
17 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.13 MCL1 BCL2 ATM
18 B cell receptor signaling pathway GO:0050853 8.92 MS4A1 IGHM CD38 BCL2

Molecular functions related to Leukemia, Chronic Lymphocytic 2 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 BH3 domain binding GO:0051434 8.62 MCL1 BCL2

Sources for Leukemia, Chronic Lymphocytic 2

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....